Using DNA Methylation to Predict Survival After Lung Cancer Surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess DNA methylation modifications in lung adenocarcinoma samples to develop a prognostic model for predicting survival outcomes after surgery. By analyzing DNA 5-methylcytosine levels in cancer tissues, the study will link these profiles to post-surgical recurrence and survival rates. Conducted across two hospitals in China, it will utilize over three years of clinical data to validate the model's accuracy and explore its potential in guiding adjuvant treatment strategies for high-risk patients. The ultimate goal is to enhance personalized treatment planning for lung adenocarcinoma patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically confirmed early-stage lung adenocarcinoma, or clinically diagnosed early-stage lung adenocarcinoma.
* Underwent surgical treatment
* Cancer tissues well paraffin-embedded or cryopreserved

Exclusion Criteria:

* Diagnosed with other serious illnesses
* Received other treatments before surgery
* Surgery to remove multiple cancerous tissues

Where it's running

• Nanjing Drum Tower hospital
  Nanjing, Jiangsu, China Recruiting

Study contacts

• Principal investigator: Qihan Chen, PhD — Nanjing University
• Study coordinator: Qihan Chen, PhD
• Email: chenqihan@nju.edu.cn
• Phone: +8613236592587

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• DBC-664 in adults with solid tumors

  A first-in-human study will test DBC-664 to see if it is safe and tolerable in adults with various advanced solid tumors and may hint at anti-tumor activity.

  Recruiting at 7 sites Phase 1 TCG Labs Soleil · Denver, Colorado and 6 other locations · NCT07705035

• Ex Vivo Drug Response Testing in Lung Adenocarcinoma with Malignant Pleural Effusions

  This study tests whether the way cancer cells from pleural effusions respond to drugs outside the body can predict how patients will respond to treatment.

  Recruiting Sheba Medical Center · Ramat Gan, Israel · NCT07636252

• Vortioxetine for cognitive problems in ALK/ROS1-positive NSCLC treated with lorlatinib

  This observational study tests whether vortioxetine can help with cognitive and neurological side effects in adults with ALK/ROS1-positive NSCLC who are taking lorlatinib.

  Recruiting Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo · Bogotá · NCT07633626

• Targeted FSRT plus bevacizumab versus hippocampus-sparing whole-brain radiation for people with lung adenocarcinoma that has spread to the brain

  This will test whether focused 5-day fractionated stereotactic radiotherapy (FSRT) combined with bevacizumab works better than hippocampus-avoidant whole-brain radiotherapy with a simultaneous boost at controlling brain metastases and protecting memory in adults with lung adenocarcinoma and extensive brain metastases.

  Recruiting at 3 sites Phase 3 Sun Yat-sen University · Chongqing, Chongqing Municipality and 2 other locations · NCT07481786

• 7-day low-carb, high-fat (ketogenic) diet to improve FDG PET/CT detection of lepidic lung adenocarcinoma

  This trial will test whether a personalized 7-day ketogenic (low-carb, high-fat) diet before an FDG PET/CT can improve detection of lepidic-predominant lung adenocarcinoma in adults with a suspicious lung nodule or confirmed diagnosis.

  Recruiting Fondazione del Piemonte per l'Oncologia · Candiolo, Torino (TO) · NCT07479095

• Partial high-dose tumor irradiation combined with immunotherapy for unresectable lung adenocarcinoma

  This trial will try giving very high-dose radiation to the central part of large, unresectable lung adenocarcinomas while preserving the surrounding immune tissue and pairing that with an immune checkpoint drug for patients who have no remaining standard treatment options.

  Recruiting Karl Landsteiner University of Health Sciences · Krems, Austria · NCT07423169

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.